¼¼°èÀÇ Â¡Å© ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : ±â¼ú Ç÷§Æûº°, Àü´Þ ¹æ¹ýº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Zinc Finger Nuclease Technology Market, By Technology Platform, By Delivery Method, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1605712
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 356 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,651,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,655,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,086,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 7¾ï 4,400¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â 21.5%ÀÇ CAGR·Î È®´ë

¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼úÀÇ ½ÃÀå ¿ªÇÐ

À¯ÀüÀÚ ÆíÁý ±¸»ó¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿øÀÌ Â¡Å© ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁø

Á¤ºÎÀÇ ±¸»óÀº ¡ũ ÇΰųªÅ¬·¹¾ÆÁ¦(ZFN) ±â¼ú ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)Àº Á¤¹ÐÀÇ·á ¹× ³ó¾÷ ÀÀ¿ëÀ» À§ÇØ ZFN ±â¼úÀ» »ç¿ëÇÏ´Â À¯ÀüÀÚ ÆíÁý ÇÁ·ÎÁ§Æ®¿¡ ¸¹Àº ÀÚ±ÝÀ» ÇÒ´çÇϰí ÀÖÀ¸¸ç, 2021³â NIH´Â À¯ÀüÀÚ ÆíÁý ¿¬±¸¿¡ 1¾ï 9,000¸¸ ´Þ·¯¸¦ ÅõÀÚÇÏ¿© Ä¡·á¿ë À¯ÀüÀÚ ÆíÁý ±â¼ú Çõ½ÅÀ» ÃËÁøÇÒ °èȹÀÔ´Ï´Ù. ÃËÁøÇß½À´Ï´Ù. ¶ÇÇÑ À¯·´¿¬ÇÕÀÇ Horizon 2020 ÇÁ·Î±×·¥Àº ZFNÀ» ÀÌ¿ëÇÑ ´Ù¾çÇÑ ÀÓ»ó½ÃÇèÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¼¼°è °¢±¹ Á¤ºÎ°¡ ZFNÀ» Æ÷ÇÔÇÑ À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ Çõ½Å °¡´É¼ºÀ» ÀÎÁ¤Çϸ鼭 ÅõÀÚ Áõ°¡¿Í À¯¸®ÇÑ Á¤Ã¥À¸·Î ÀÇ·á¿¡¼­ ³ó¾÷¿¡ À̸£±â±îÁö ´Ù¾çÇÑ »ê¾÷¿¡¼­ äÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ FDA¿Í EMA¿Í °°Àº ±â°üÀÌ À¯ÀüÀÚ ÆíÁý Ä¡·á °ü·Ã °¡À̵å¶óÀÎÀ» ¸íÈ®È÷ ÇÏ´Â µî ±ÔÁ¦ ȯ°æµµ °³¼±µÇ°í ÀÖÀ¸¸ç, ZFN ½ÃÀå È®´ë¿¡ ±â¿©ÇÒ ¼ö Àִ ȯ°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ý¸í°øÇÐ ±â¾÷, ¿¬±¸±â°ü, Á¤ºÎ±â°üÀÇ Çù·ÂÀ¸·Î À¯ÀüÁúȯ ¹× À¯ÀüÀÚº¯Çü ÀÛ¹°¿¡ ´ëÇÑ ZFNÀÇ Àû¿ëÀÌ Áö¼ÓÀûÀ¸·Î °­È­µÇ°í ÀÖ½À´Ï´Ù.

¡ũ ÇΰŴºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : ÁÖ¿ä °í·Á»çÇ×

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¿¬Æò±Õ ¾à 21.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â¼ú Ç÷§Æû ¼¼ºÐÈ­¿¡ µû¶ó ¸ðµâ½Ä ¾î¼Àºí¸®´Â 2023³â¿¡ °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» º¸¿´½À´Ï´Ù.

Àü´Þ ¹æ¹ýÀÇ ¼¼ºÐÈ­¿¡ µû¸£¸é 2023³â¿¡´Â Àκñº¸(In Vivo)°¡ ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÔ¿øÀ¸·Î ºÎ»óÇß½À´Ï´Ù.

¡ũÇΰŴºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¡ũ ÇΰŴºÅ¬·¹¾ÆÁ¦ ±â¼ú ¼¼°è ½ÃÀåÀº ±â¼ú Ç÷§Æû, Àü´Þ ¹æ¹ý, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº ±â¼ú Ç÷§Æû¿¡ µû¶ó ¸ðµâ½Ä Á¶¸³°ú OPEN(Oligomerized Pool Engineering)ÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´µ¸ç, ¸ðµâ½Ä Á¶¸³ ±â¼ú Ç÷§ÆûÀº À¯ÀüÀÚ ÆíÁý Åø ¼³°èÀÇ À¯¿¬¼º°ú È¿À²¼ºÀ¸·Î ÀÎÇØ À¯ÀüÀÚ ÆíÁý ±â¼ú ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù, OPEN(Oligomerized Pool Engineering)Àº ƯÁ¤ ¿ëµµ¿¡ ƯȭµÈ Á¤¹ÐÇÑ À¯ÀüÀÚ ÆíÁý ±â´ÉÀ» Á¦°øÇϸç, ¸ðµâ½Ä ¾î¼Àºí¸® ±â¼ú Ç÷§ÆûÀº À¯ÀüÀÚ ÆíÁý Åø ¼³°èÀÇ À¯¿¬¼º°ú È¿À²¼ºÀ¸·Î ÀÎÇØ À¯ÀüÀÚ ÆíÁý ±â¼ú ½ÃÀåÀ» ¼±µµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀº Àü´Þ ¹æ¹ý¿¡ µû¶ó »ýü ³»¿Í »ýü ¿ÜÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. »ýü³» Àü´Þ ¹æ¹ýÀº ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â »ýü³» Á÷Á¢ Àû¿ëÀÌ °¡´ÉÇϹǷΠº¸´Ù È¿À²ÀûÀÎ À¯ÀüÀÚ ÆíÁýÀÌ °¡´ÉÇϱ⠶§¹®ÀÔ´Ï´Ù. ±× µÚ¸¦ ÀÌ¾î »ýü ¿Ü´Â »ýü ¿Ü ¼¼Æ÷¿¡¼­ ÀçµµÀÔ Àü¿¡ Ç¥ÀûÈ­µÈ ÆíÁýÀ» ¼öÇàÇÕ´Ï´Ù.

¡ũ ÇΰŴºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : Áö¿ªº° ºÐ¼®

ºÏ¹Ì´Â ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦(ZFN) ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀ¸·Î, Á¤ºÎ Áö¿ø, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, źźÇÑ »ý¸í°øÇÐ »ê¾÷ ¼ºÀå¿¡ ÈûÀÔ¾î 2022³â ¹Ì±¹ Á¤ºÎ´Â À¯ÀüÀÚ ÆíÁý ±¸»ó¿¡ 5¾ï ´Þ·¯ ÀÌ»óÀÇ ÀÚ±ÝÀ» ¹èÁ¤ÇÏ¿© Èñ±ÍÁúȯÀÇ À¯ÀüÀÚ Ä¡·á µî ´Ù¾çÇÑ ÀÇ·á ¿ëµµ¿¡ ZFN ±â¼ú äÅÿ¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á µî ´Ù¾çÇÑ ÀÇ·á ¿ëµµ¿¡¼­ ZFN ±â¼ú äÅÿ¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ª¿¡´Â Sangamo Therapeutics¿Í °°Àº ¼±µµÀûÀÎ »ý¸í°øÇÐ ±â¾÷µµ ÀÖÀ¸¸ç, ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè°ú ͏®Æ÷´Ï¾Æ ´ëÇаú °°Àº ±â°ü°úÀÇ Á¦ÈÞ¸¦ ÅëÇØ ZFNÀ» ÀÌ¿ëÇÑ À¯ÀüÀÚ ÆíÁýÀ» ÅëÇÑ À¯Àü¼º Áúȯ Ä¡·á¸¦ Àû±ØÀûÀ¸·Î ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ FDAÀÇ À¯ÀüÀÚ ÆíÁý Á¦Ç° ½ÂÀÎ ÀýÂ÷ °£¼ÒÈ­¸¦ À§ÇÑ ³ë·ÂÀº ZFN ±â¼ú µµÀÔ¿¡ À¯¸®ÇÑ ±ÔÁ¦ ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº ¿µ±¹°ú µ¶Àϰú °°Àº ±¹°¡µéÀÌ À¯ÀüÀÚ ÆíÁý ¿¬±¸¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸¸ç, ÀÌ´Â ÁÖ¿ä ±â°ü ¹× »ý¸í°øÇÐ ±â¾÷°úÀÇ °øµ¿ ¿¬±¸¸¦ ÅëÇØ ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹°ú Àεµ¿Í °°Àº ±¹°¡µéÀÇ ¿¬±¸ ÅõÀÚ Áõ°¡¿Í »ý¸í°øÇÐ »ýŰèÀÇ ¼ºÀåÀ¸·Î ÀÎÇØ À¯¸ÁÇÑ ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

¡ũ ÇΰŴºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : °æÀï ±¸µµ

¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦(ZFN) ±â¼ú ½ÃÀå °æÀï ±¸µµ´Â Sangamo Therapeutics¿Í Precision Biosciences¸¦ ÇʵηΠÇÑ ºÏ¹Ì ±â¾÷ÀÌ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡ º»»ç¸¦ µÐ Sangamo Therapeutics´Â Ç÷¿ìº´ À¯ÀüÀÚ Ä¡·á¸¦ À§ÇØ È­ÀÌÀÚ¿ÍÀÇ Á¦ÈÞ¸¦ ÅëÇØ À¯ÀüÀÚ Áúȯ¿¡ ´ëÇÑ ZFN ±â¹Ý Ä¡·á¹ýÀ» Áö¼ÓÀûÀ¸·Î °³¹ßÇϰí ÀÖÀ¸¸ç, 2022³â¿¡´Â ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ZFN ±â¹Ý Ä¡·áÁ¦¸¦ °³¹ßÇϱâ À§ÇØ Sanofi¿Í Á¦ÈÞ¸¦ ü°áÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ZFN ±â¹Ý ÀÚ°¡¸é¿ªÁúȯ Ä¡·áÁ¦¸¦ °³¹ßÇϱâ À§ÇØ »ç³ëÇÇ¿Í Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ü°áÇߴµ¥, ÀÌ´Â ZFN ±â¼ú¿¡ ´ëÇÑ ½Å·Ú°¡ ³ô¾ÆÁø °ÍÀ» ¹Ý¿µÇÕ´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ ¾÷üÀÎ Precision Biosciences´Â °â»óÀûÇ÷±¸Áõ°ú °°Àº ´Ù¾çÇÑ À¯Àü¼º ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ ZFN ±â¼úÀ» ÀÌ¿ëÇÑ ÀÓ»ó½ÃÇè¿¡¼­ ÁøÀüÀ» º¸À̰í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â ZFNÀÇ ÀÀ¿ëÀ» °³¼±Çϱâ À§ÇÑ »ý¸í°øÇÐ ±â¾÷°ú Çаè¿ÍÀÇ °øµ¿¿¬±¸ µîÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Áß±¹ ¹ÙÀÌ¿ÀÅ×Å© »ýŰèÀÇ ºÎ»óÀÌ ½ÃÀå ¿ªÇÐ º¯È­¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÇöÁö ±â¾÷Àº Á¤ºÎ Áö¿ø ¿¬±¸ ±¸»óÀÇ Áö¿øÀ» ¹Þ¾Æ ZFNÀ» Æ÷ÇÔÇÑ À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼úÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼úÀÇ ½ÃÀå ±¸µµ

Á¦7Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : ±â¼ú Ç÷§Æûº°

Á¦8Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : Àü´Þ ¹æ¹ýº°

Á¦9Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦ ±â¼ú ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

The Zinc Finger Nuclease Technology Market size was valued at USD 744 Million in 2023, expanding at a CAGR of 21.5% from 2024 to 2032.

The Zinc Finger Nuclease (ZFN) technology market focuses on the development and application of highly specific gene-editing tools used for targeted DNA modification. ZFNs are used in a variety of research and therapeutic applications, including gene therapy, crop development, and disease modeling. As the potential of gene editing becomes increasingly recognized, the demand for precise, reliable, and efficient gene-editing tools has grown. According to a report from the National Institutes of Health, ZFN technology is being explored for its potential to correct genetic defects, especially in rare genetic disorders. The market benefits from advancements in biotechnology, as ZFNs offer a high degree of specificity, reducing off-target effects compared to other gene-editing technologies like CRISPR. However, high development costs and regulatory hurdles related to the use of ZFNs in human therapy pose challenges. Despite this, ongoing research, collaborations between biotech firms, and government support for gene-editing initiatives are opening up substantial market opportunities in healthcare, agriculture, and environmental sustainability.

Zinc Finger Nuclease Technology Market- Market Dynamics

Government Support for Gene-Editing Initiatives Drives Growth in the Zinc Finger Nuclease Technology Market

Government initiatives are significantly boosting the growth of the Zinc Finger Nuclease (ZFN) technology market. For instance, the U.S. National Institutes of Health (NIH) has allocated substantial funding for gene-editing projects, including those using ZFN technology for precision medicine and agricultural applications. In 2021, the NIH invested $190 million in gene-editing research, fostering innovation in therapeutic gene editing. Additionally, the European Union's Horizon 2020 program has supported various ZFN-based clinical trials. As governments globally acknowledge the transformative potential of gene-editing technologies, including ZFN, increased investments and favorable policies are driving adoption in industries ranging from healthcare to agriculture. The regulatory environment has also improved, with agencies such as the FDA and EMA working on clearer guidelines for gene-editing therapies, creating a conducive environment for ZFN market expansion. Furthermore, collaborations between biotech firms, research institutes, and governmental bodies continue to enhance the application of ZFN in genetic diseases and genetically modified crops.

Zinc Finger Nuclease Technology Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 21.5% over the forecast period (2024-2032)

Based on Technology Platform segmentation, Modular Assembly was predicted to show maximum market share in the year 2023

Based on Delivery Method segmentation, In Vivo was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Zinc Finger Nuclease Technology Market- Segmentation Analysis:

The Global Zinc Finger Nuclease Technology Market is segmented on the basis of Technology Platform, Delivery Method, End-User, and Region.

The market is divided into two categories based on Technology Platform: Modular Assembly and OPEN (Oligomerized Pool Engineering). The Modular Assembly technology platform is expected to lead the Zinc Finger Nuclease Technology market due to its flexibility and efficiency in designing gene-editing tools. OPEN (Oligomerized Pool Engineering) follows, offering targeted and precise gene-editing capabilities for specific applications.

The market is divided into two categories based on the Delivery Method: In Vivo and Ex Vivo. In Vivo delivery method is anticipated to lead the Zinc Finger Nuclease Technology market, owing to its direct application in living organisms, allowing for more efficient gene editing. Ex Vivo follows, offering targeted editing in cells outside the organism before reintroduction.

Zinc Finger Nuclease Technology Market- Geographical Insights

North America is the leading region in the Zinc Finger Nuclease (ZFN) technology market, primarily due to significant government support, advanced healthcare infrastructure, and robust biotech industry growth. In 2022, the U.S. government allocated over $500 million in funding for gene-editing initiatives, contributing to the adoption of ZFN technology in various medical applications, such as gene therapies for rare diseases. The region also boasts major biotech companies like Sangamo Therapeutics, which is actively advancing ZFN-based gene-editing treatments for genetic disorders, with ongoing clinical trials and collaborations with institutions like the University of California. Additionally, the U.S. FDA's initiatives to streamline approval processes for gene-editing products have created a favorable regulatory environment for ZFN technology adoption. Europe follows closely with countries like the UK and Germany, which are increasingly focusing on gene-editing research, evidenced by collaborations between leading institutions and biotech companies. Furthermore, Asia-Pacific is emerging as a promising market due to increased research investments and a growing biotech ecosystem in countries like China and India.

Zinc Finger Nuclease Technology Market- Competitive Landscape:

The competitive landscape of the Zinc Finger Nuclease (ZFN) technology market is largely dominated by North American companies, with key players like Sangamo Therapeutics and Precision Biosciences leading the charge. Sangamo Therapeutics, headquartered in the U.S., is recognized for its ongoing efforts to develop ZFN-based therapies for genetic disorders, including its collaboration with Pfizer to advance gene therapies for hemophilia. In 2022, Sangamo entered into a strategic partnership with Sanofi to develop ZFN-based treatments for autoimmune diseases, reflecting the growing confidence in ZFN technology. Another notable player, Precision Biosciences, has made strides in clinical trials using ZFN technology to address various genetic conditions, such as sickle cell disease. In Europe, notable developments include collaborations between biotech firms and academic institutions to refine ZFN applications. Meanwhile, in the Asia-Pacific region, China's rising biotech ecosystem is contributing to a shift in the market dynamics, with local companies increasing their focus on gene-editing technologies, including ZFNs, supported by government-backed research initiatives.

Recent Developments:

In May 2024, Researchers from Hiroshima University and the Japanese National Institute of Advanced Industrial Science enhanced Zinc Finger Nuclease (ZFN) technology using machine learning-driven modular assembly systems. This advancement improves gene editing efficiency, offering a promising tool for treating genetic disorders.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ZINC FINGER NUCLEASE TECHNOLOGY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL ZINC FINGER NUCLEASE TECHNOLOGY MARKET, BY TECHNOLOGY PLATFORM- MARKET ANALYSIS, 2019 - 2032

GLOBAL ZINC FINGER NUCLEASE TECHNOLOGY MARKET, BY DELIVERY METHOD- MARKET ANALYSIS, 2019 - 2032

GLOBAL ZINC FINGER NUCLEASE TECHNOLOGY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL ZINC FINGER NUCLEASE TECHNOLOGY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Zinc Finger Nuclease Technology Market Overview

2. Executive Summary

3. Zinc Finger Nuclease Technology Key Market Trends

4. Zinc Finger Nuclease Technology Industry Study

5. Zinc Finger Nuclease Technology Market: COVID-19 Impact Analysis

6. Zinc Finger Nuclease Technology Market Landscape

7. Zinc Finger Nuclease Technology Market - By Technology Platform

8. Zinc Finger Nuclease Technology Market - By Delivery Method

9. Zinc Finger Nuclease Technology Market - By End-User

10. Zinc Finger Nuclease Technology Market- By Geography

11. Key Vendor Analysis- Zinc Finger Nuclease Technology Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â